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Abstract 
 
Epithelial-to-mesenchymal transition (EMT) promotes cell motility, which is important for 
the metastasis of malignant cells, and blocks CD95-mediated apoptotic signaling triggered by 
immune cells and chemotherapeutic regimens. CD95L, the cognate ligand of CD95, can be 
cleaved by metalloproteases and released as a soluble molecule (cl-CD95L). Unlike 
transmembrane CD95L, cl-CD95L does not induce apoptosis but triggers cell motility. 
Electron paramagnetic resonance was used to show that EMT and cl-CD95L treatment both 
led to augmentation of plasma membrane fluidity that was instrumental in inducing cell 
migration. Compaction of the plasma membrane is modulated, among other factors, by the 
ratio of certain lipids such as sphingolipids in the membrane. An integrative analysis of gene 
expression in NCI tumor cell lines revealed that expression of ceramide synthase-6 (CerS6) 
decreased during EMT. Furthermore, pharmacological and genetic approaches established 
that modulation of CerS6 expression/activity in cancer cells altered the level of C16-
ceramide, which in turn influenced plasma membrane fluidity and cell motility. Therefore, 
this study identifies CerS6 as a novel EMT-regulated gene that plays a pivotal role in the 
regulation of cell migration.  
 
Keywords: Ceramide, EMT, Fas, Fluidity, Ceramide synthase, Migration. 
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Introduction 
CD95L (also known as FasL) is a transmembrane ligand that binds to the so-called death 
receptor CD95 (also known as Fas/APO1). Metalloproteases can cleave CD95L to produce 
the soluble ligand cl-CD95L. While transmembrane CD95L is a potent apoptosis inducer that 
participates in immune surveillance and tolerance (see review 33), cl-CD95L cannot induce 
apoptosis, but instead triggers the motility of cancer cells and activated T lymphocytes 12, 15, 35 
and aggravates inflammation 23, 35. Binding of transmembrane CD95L to CD95 leads to 
formation of the death-inducing signaling complex (DISC), which contains the Fas-associated 
via death domain (FADD) adaptor protein and caspases -8 and -10 14. This complex plays a 
pivotal role in the initiation of apoptotic signaling. Cells can be classified as type I or type II 
according to the efficiency with which DISC forms and their reliance on the mitochondrion-
driven apoptotic signal to implement the CD95-mediated apoptotic signal 14. We previously 
showed that type II cells are of epithelial lineage, whereas type I cells are mesenchymal-like 1. 
Type II cells are more sensitive to the CD95-mediated apoptotic signal than type I cells; 
therefore, it was concluded that cancer cells undergoing epithelial-to-mesenchymal transition 
(EMT) reprogram their apoptotic machinery to resist CD95-mediated cell death 1. These 
findings encouraged us to investigate whether EMT alters the cellular response to cl-CD95L, 
i.e., motility.  
Sphingolipids (SLs) belong to a class of lipids whose members play multiple roles in 
eukaryotic cells. SLs are important structural components of membranes and are second 
messengers that regulate cell growth, differentiation, and death 10. Ceramide (N-acyl-D-
erythro-sphingosine) can be generated via hydrolysis of sphingomyelin by 
sphingomyelinases, or via ceramide synthase (CerS)-mediated de novo ceramide biosynthesis. 
This pathway involves acylation of sphinganine with fatty acyl-CoAs of chain lengths of 
C14–C26 to produce dihydroceramide. Alternatively, CerS can synthesize ceramide by the 
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salvage pathway through direct acylation of sphingosine, which is derived from SL 
catabolism 10. Ceramide synthesis is orchestrated by six mammalian CerS proteins, each of 
which produces ceramides with restricted acyl chain lengths 20. Among these proteins, 
ceramide synthase isoform 6 (CerS6) was most recently cloned 38. Although most studies of 
ceramides have analyzed their impact on apoptotic signaling, these lipids also promote the 
formation of ordered liquid phases called lipid rafts, whose accumulation rigidifies the plasma 
membrane 29. Ceramides form rigid ceramide-enriched domains when their N-acyl chain is 
longer than C12 5, 7 and lead to an overall decrease in ordered lipid membranes in CerS2-null 
mice 30. The biophysical properties of hepatocyte membranes are modified in CerS2-null 
mice, including increased fluidity 25, which is directly associated with changes in the SL 
composition. Furthermore, high plasma membrane fluidity is correlated with enhanced 
migratory/invasive ability of tumor cells 22, 31, 34, 40, which might be due to the enhanced 
deformability of these cells 22. These observations raise the possibility that EMT alters the 
level of SL biosynthesis to increase membrane fluidity, which in turn promotes cell migration, 
a phenotypic change associated with EMT.  
In this study, we demonstrate that EMT enhances CD95-mediated signaling to promote cell 
migration. An epithelial/mesenchymal comprehensive microarray analysis was used to show 
that CerS6 is differentially expressed during EMT and to provide evidence that the level of 
CerS6 expression controls the C16-ceramide membrane content of breast cancer cells, which 
in turn modulates their plasma membrane fluidity and motility. 
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Results 
EMT and cl-CD95L-induced cell migrations are correlated with increased membrane 
fluidity. Using a transcriptomic analysis of 22 tumor cell lines of various histological origins 
[National Cancer Institute (NCI)] that respond differently to cytotoxic CD95L, we previously 
demonstrated that type I cells display a mesenchymal-like phenotype, whereas type II cells 
have an epithelial-like gene signature 1. Cl-CD95L does not induce cell death but triggers cell 
motility 35; therefore, we investigated whether EMT modifies the response of tumor cells to a 
CD95-driven pro-migratory cue. Using a Boyden chamber assay, cell motility was evaluated 
in various mesenchymal and epithelial-like breast cancer cells in the presence or absence of 
cl-CD95L (Fig. 1A). While mesenchymal-like cells migrated spontaneously across pore-
containing membranes in the absence of cl-CD95L, epithelial cells did not (Fig. 1A). In 
addition, cl-CD95L treatment increased mesenchymal cell migration, but not epithelial cell 
migration (Fig. 1A). This suggests that CD95-mediated cell migration is blocked in the latter 
cells and/or promoted in the former cells.  
Increased membrane fluidity can promote the invasion/motility of tumor cells 22, 31, 34, 40; 
therefore, we next evaluated the membrane lipid packing densities of a large set of tumor cell 
lines. To this end, electron paramagnetic resonance (EPR) was used to quantify the S 
parameter, a biophysical parameter that is inversely correlated with membrane fluidity 2. The 
S parameter was higher in epithelial tumor cells than in mesenchymal tumor cells 
(0.496±0.0088, n=17 versus 0.467±0.0215, n=20, p≤0.001; Fig. 1B), indicating that EMT led 
to membrane fluidization. Confirming this, membrane fluidity was higher in mesenchymal 
breast cancer cells than in epithelial breast cancer cells (0.464±0.0043, n=6 versus 
0.476±0.0069 n=6, p=0.0043; Fig. 1B). In addition, the membrane fluidity of mesenchymal-
like MDA-MB-231 breast tumor cells increased following cl-CD95L treatment (Fig. 1C). To 
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determine the role of plasma membrane fluidity in cell migration, MDA-MB-231 cells were 
pretreated with non-cytotoxic doses of the membrane stabilizing agent ursodeoxycholic acid 
(UDCA) 17 or the cyclopropyl fatty acid ester A2C, a compound that fluidifies plasma 
membranes 36. Pre-incubation of MDA-MB-231 cells with UDCA slightly decreased basal 
membrane fluidity, although not significantly; however, this treatment abrogated the CD95-
mediated increase in plasma membrane fluidity (Fig. 1C). By contrast, A2C treatment 
significantly enhanced both basal and CD95-induced cell membrane fluidity (Fig. 1C). 
Importantly, CD95-mediated migration of MDA-MB-231 cells was completely abolished by 
UDCA treatment but stimulated by A2C treatment (Fig. 1D). Collectively, these data indicate 
that plasma membrane fluidity increases during EMT and that this biophysical parameter has 
a pivotal function in both EMT-driven and CD95-mediated cell motility.  
 
EMT triggers down-regulation of CerS6. Cholesterol and SLs participate in plasma 
membrane fluidity and compaction; therefore, we next investigated whether enzymes 
involved in the biosynthesis of these lipids are up- or down-regulated during EMT. To this 
end, a transcriptomic meta-analysis was performed using data from 22 tumor cell lines. These 
cell lines were epithelium-like or mesenchymal-like 26 and were previously categorized as 
type II and type I, respectively, based on their sensitivity to the CD95-mediated apoptotic 
signal 1. Data were extracted from the NCBI Gene Expression Omnibus repository. The SAM 
tool (Significance Analysis of Microarrays) was used to identify 168 genes that were 
significantly up-regulated in type II cells and 542 genes that were significantly up-regulated 
in type I cells (Supporting Tables 1 and 2, respectively). Further analysis revealed that 
expression of CerS6, also known as LASS6, was significantly higher in type II (epithelial-like) 
cells than in type I (mesenchymal-like) cells. This in silico analysis was next validated 
experimentally at the mRNA (Fig. 2A). To rule out the possibility that this ceramide synthase 
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was only associated with the way tumor cells respond to an apoptotic inducer, we next 
evaluated whether CerS6 was differentially expressed between NCI cell lines showing an 
epithelial or mesenchymal-like gene signature 26. An in silico analysis performed on tumor 
cell lines classified as epithelial or mesenchymal-like cells according to their expression 
levels of E-cadherin (CDH1)(epithelial marker) and Vimentin (mesenchymal marker) 
confirmed that the level of CerS6 transcripts was reduced in mesenchymal-like cancer cells as 
compared to their counterparts exhibiting an epithelial-like gene signature (Fig.S1). To 
confirm that CerS6 expression was down-regulated during EMT, we first evaluated the 
protein expression levels of two EMT markers, namely E-cadherin and Vimentin, in 47 NCI-
60 tumor cell lines (Fig.S2A) that have previously been reported to display an Epithelial or 
mesenchymal-like phenotype24. We ranked these tumor cells based on their E-
cadherin/Vimentin ratio (Fig. 2B) into three groups: i) an epithelial group with high E-
cadherin expression, ii) an undefined group that either expressed equally the two markers or 
did not express them, and iii) a mesenchymal group with high Vimentin expression (Fig. 2B). 
Minor differences were found when we compared our classification with the one from Peter’s 
group24. Indeed, among the 47 tumor cell lines tested, only five of them (OSCAR-5, PC3, 
SW620, SR and IGROV-1) showed a difference of classification between the two studies. 
The protein expression levels of CerS6 were significantly increased in epithelial cells as 
compared to mesenchymal tumor cells (Fig. 2C). This suggests that CerS6 is a novel EMT-
regulated gene, the expression of which in epithelial cells may alter the SL composition of 
plasma membranes. 
To confirm that CerS6 expression was regulated during EMT, the level of CerS6 expression 
was evaluated in various well-established EMT models. Primary human mammary epithelial 
cells (HMECs) were used that have undergone sequential retroviral infections to express the 
telomerase catalytic subunit (hTERT), the large-T and small-t antigens of SV40, and the 
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oncogenic allele of H-Ras (H-RasV12), and have thereby been converted to aggressive tumor 
cells 4, 8. This stepwise EMT cellular model system, which gives rise to mammary cells 
exhibiting epithelial (E-cadherin) or mesenchymal-like (vimentin) gene signatures, confirmed 
that CerS6 expression was extinguished during EMT (Fig. 2D). To confirm this, CerS6 
expression was evaluated in the immortal human mammary epithelial cell line MCF10A and 
its K-RasV12-expressing counterpart. Expression of the mesenchymal marker N-cadherin 
(CDH-2) was higher and expression of the epithelial marker E-cadherin was lower in 
MCF10A-K-RasV12 cells than in MCF10A cells, consistent with the former cells having 
undergone EMT (Fig.S2B and 19). Interestingly, EMT triggered by K-RasV12 expression was 
accompanied by a decrease in the protein level of CerS6 (Fig.S2B). Stimulation with TGF-β 
can trigger MCF10A and HMEC-TR breast epithelial cells to undergo EMT 11. This inducible 
EMT model was used to establish that CerS6 expression is consistently reduced during EMT 
(Fig.S2C).  
Breast cancer is a heterogeneous pathology, with tumors being classified into various 
subtypes based on their genomic and clinical features 32. While luminal A and B tumors 
express epithelial markers, such as E-cadherin, basal-like cancer cells have a mesenchymal-
like phenotype and express markers such as vimentin and N-cadherin 27. Importantly, 
prognosis is poorer in patients with basal breast tumors than in patients with luminal breast 
tumors, and EMT is associated with tumor aggressiveness and an increased risk of metastatic 
dissemination in these patients 27. A meta-analysis of breast cancer patients using the bc-
GenExMiner tool 13 showed that CerS6 expression was lower in basal tumors than in luminal 
tumors (Fig. S3). Overall, these data strongly support that CerS6 expression is down-
regulated in tumor cells undergoing EMT. 
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Overexpression of CerS6 in mesenchymal tumor cells decreases membrane fluidity and 
inhibits cell motility. To characterize the cellular function of CerS6 during EMT, CerS6 was 
overexpressed in two mesenchymal breast cancer cells, MDA-MB-231 and MDA-MB-468. 
Transduction of these cells with a CerS6-encoding retroviral vector generated stable cell 
populations overexpressing CerS6 (Fig. 3A). Strikingly, CerS6 overexpression did not alter 
the expression levels of the mesenchymal marker vimentin or the epithelial marker E-cadherin 
(Fig. 3A), suggesting that EMT controlled CerS6 expression but not vice versa. Lipidomic 
analysis using gas chromatography and mass spectrometry showed that CerS6 overexpression 
significantly increased the C16-ceramide contents of both cell lines (Fig. 3B). However, this 
increase did not alter the total ceramide content (Tables 1 and 2), indicating that a 
compensatory process served to ensure that the total ceramide content did not change in 
CerS6-overexpressing cells. Modulation of CerS6 expression will affect the acyl-CoA pool, 
which is required for the biosynthesis of glycerophospholipids, including 
phosphatidylcholine, phosphatidylinositol, phosphatidylserine and phosphatidylethanolamine; 
therefore, the levels of these lipids were evaluated in MDA-MB-231 cells, MDA-MB-468 
cells, and their CerS6-overexpressing counterparts. CerS6 overexpression did not 
significantly affect the glycerophospholipid content (Tables 1 and 2). Ceramide can be 
metabolized to sphingomyelin, the major plasma membrane SL; therefore, sphingomyelin 
content was also monitored. Whereas CerS6 overexpression did not affect the total amount of 
sphingomyelin, the level of C16-sphingomyelin was significantly higher in CerS6-
overexpressing cells than in control cells (Tables 1 and 2). These findings show that CerS6 
overexpression leads to the accumulation of C16:0 ceramide, which is metabolized to more 
complex SLs such as C16:0 sphingomyelin. CerS6 overexpression slightly, but significantly, 
reduced basal membrane fluidity (Fig. 3C) and prevented cl-CD95L-induced membrane 
fluidization (Fig. 3C). In addition, CerS6 overexpression in these mesenchymal-like breast 
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cancer cells reduced basal and inhibited CD95-mediated cell motility (Fig. 3D). These 
findings indicate that ectopic CerS6 expression in mesenchymal-like tumor cells increases 
levels of C16:0 ceramide and its derivative C16:0 sphingomyelin, which in turn reduces 
membrane fluidity and inhibits cell motility. 
 
Down-regulation of CerS6 in epithelial tumor cells enhances membrane fluidity and 
stimulates cell migration. To confirm that CerS6 reduces membrane fluidity and cell 
motility, a pharmacological inhibitor was used to perturb CerS6 activity in epithelial-like 
breast cancer cells, and the effects of this on plasma membrane fluidity and cell migration 
were determined. Fumonisin B1 (FB1), a mycotoxin produced by Fusarium moniliforme, 
selectively inhibits CerS activity 37. When the epithelial cell line MCF7 was treated with a 
non-cytotoxic concentration of FB1 for 48 hours, basal and CD95-induced membrane fluidity 
were slightly, but significantly, increased (Fig. S4A). In addition, FB1 treatment enhanced 
basal and CD95-mediated cell migration (Fig. S4B). To confirm these data, CerS6 expression 
was down-regulated in two epithelial breast cancer cells, MCF7 and T47D. These cells were 
transduced with lentiviruses encoding simultaneously GFP and shRNAs targeting different 
regions of CerS6 mRNA (shCerS6). All MCF7 cells and more than 80% of T47D cells were 
infected (GFP-positive) (Fig. 4A). Consistent with the FACS analyses, CerS6 expression was 
efficiently silenced in MCF7 cells and to a lesser extent in T47D cells following transduction 
with lentiviruses containing either shCerS6 (Fig. 4B). Furthermore, the reduction in CerS6 
expression did not affect expression of EMT-related target genes, including E-cadherin and 
vimentin (Fig. 4B), confirming that CerS6 is not an EMT master regulator gene.  
Lipidomic analysis showed that down-regulation of CerS6 expression in MCF7 and T47D 
cells did not alter their total ceramide contents (see insets in Fig. 4C and Tables 3 and 4), 
whereas the level of C16:0 ceramide was significantly reduced (Fig. 4C). By contrast, down-
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regulation of CerS6 expression was associated with a slight increase in the level of C18:0, 
C20:0, C24:0, or C24:1 ceramide, according to the cell line (Fig. 4C). CerS6 knockdown 
increased basal and CD95-mediated plasma membrane fluidity (Fig. 4D) and cell migration 
(Fig. 4E) in these epithelial cancer cells. Of note, the pro-migratory effect of cl-CD95L was 
less pronounced in shCerS6-treated MCF7 cells than in shCerS6-treated T47D cells (Fig. 4D). 
This may be because CerS6 expression was down-regulated more efficiently in MCF7 cells 
than in T47D cells (Fig. 4B), which led to a dramatic increase in the basal motility of MCF7 
cells that might partially mask CD95-induced cell motility (Fig. 4E). Overall, these findings 
demonstrate that down-regulation of CerS6 expression in epithelial-like tumor cells enhances 
cell migration without affecting EMT.  
 
C16-ceramide, the product of CerS6, reduces membrane fluidity and cell migration. 
Finally, to show that CerS6 overexpression induced cell membrane compaction and thereby 
inhibited cell migration, we evaluated the impact of its main lipid product, C16-ceramide. To 
this end, two mesenchymal breast cancer cells were incubated for 24 hours with a non-
cytotoxic concentration of C16:0 ceramide (Fig. 5A) and membrane fluidity and cell motility 
were analyzed. While the addition of C16:0 ceramide slightly increased the basal S parameter 
in these cell lines (Fig. 5B), it completely inhibited the CD95-mediated increase in membrane 
fluidization (Fig. 5B). More importantly, basal and CD95-mediated migration of 
mesenchymal breast tumor cells was impaired when they were cultured in medium containing 
a non-cytotoxic concentration of C16-ceramide (Fig. 5C). These results indicate that 
exogenous C16-ceramide is adsorbed and retained in cell membranes, and confirm that an 
increased level of C16-ceramide, which is observed upon CerS6 overexpression, is 
instrumental in preventing CD95-mediated membrane fluidization and cell migration.  
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Discussion 
EMT is a crucial process in embryonic development that can be partly phenocopied in 
carcinogenesis, giving rise to aggressive tumors with increased metastatic capacity. In the 
present study, we demonstrate that CerS6 expression is down-regulated during EMT, leading 
to increased plasma membrane fluidity, which in turn promotes cell migration.  
Cells undergoing EMT exhibit morphological changes and increased motility, which is linked 
to striking reductions in expression of epithelial markers, such as E-cadherin, and enhanced 
expression of mesenchymal markers, such as vimentin and N-cadherin. Using 
pharmacological and genetic approaches, we showed that the level of CerS6 expression does 
not affect EMT per se. This seems to disagree with data from the Hakomori group showing 
that pharmacological inhibition of glucosylceramide synthase or the addition of one of its 
products, gangliotetraosylceramide (Gg4), modulates cell motility and changes the expression 
ratio of EMT-related genes in various cellular models, including the epithelial breast cancer 
cell line MCF-7 6. One explanation for this discrepancy is that the carbohydrate moiety 
complexity of Gg4 allows it to target other unidentified molecular targets and thereby exert 
additional effects on EMT compared to C16-ceramide and C16-sphingomyelin. In support of 
this hypothesis, the ganglioside GM2, whose expression is also decreased by inhibition of 
glucosylceramide synthase activity, does not reverse TGF-β-induced EMT of NMuMG cells, 
whereas Gg4 does 6. In addition to the carbohydrate moiety, our findings provide insight into 
the pivotal roles played by the C16:0 fatty acid chain of ceramide and its derivatives in 
biological functions such as cell motility.  
Okazaki and colleagues recently showed that sphingomyelin impairs CXCL12-mediated cell 
migration 3. The current study shows that CerS6 overexpression is associated with an increase 
in the C16:0 sphingomyelin content; therefore, we cannot exclude the possibility that 
sphingomyelin contributes to the phenotypes observed. However, given that CD95-mediated 
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membrane fluidization and cell migration are inhibited by pre-incubation with exogenous 
C16-ceramide for a short period (60 minutes), C16-ceramide itself likely contributes to the 
modulation of membrane fluidity and cell motility during EMT. 
Glycosphingolipids (GSLs) modulate various cell signaling pathways by regulating the 
activities of tyrosine kinase receptors 9, 21, and more specifically, epidermal growth factor 
(EGF) receptor 9. Based on our recent findings showing that cl-CD95L induces a 
phosphoinositide 3-kinase (PI3K)-driven pro-migratory signaling pathway in mesenchymal 
breast tumor cells via recruitment of EGF receptor 18, we investigated whether C16-ceramide 
can prevent this signaling pathway. Analysis of phosphorylation at serine 473 of Akt, a 
hallmark of PI3K activation, demonstrated that C16-ceramide did not affect the CD95-
mediated PI3K signaling pathway (Fig. S5). This indicates that C16-ceramide does not 
interfere with the initial steps of pro-migratory CD95-mediated cell signaling. The 
mechanistic link between CD95L and plasma membrane fluidization remains uncertain and 
requires further investigation. 
Exogenous short-chain ceramides such as C2-ceramide inhibit migration of lung cancer cells 
in response to nicotine via activation of protein phosphatase 2A 39. This previous study 
suggested that C2-ceramide directly affects cell migration. However, the authors did not 
eliminate the possibility that C2-ceramide that accumulates in the lipid bilayers of pulmonary 
cells is hydrolyzed by acid ceramidase to form sphingosine that enters the salvage pathway to 
form new ceramides through the activities of CerS such as CerS6. In this regard, it would be 
interesting to investigate the activity of CerS6 in pulmonary epithelial cells exposed to 
nicotine.  
CerS6 expression was modulated in various cancer cell lines with epithelial- or mesenchymal-
like gene signatures, in well-defined inducible EMT models, and also in a large panel of 
women affected by luminal or basal breast cancers (Fig. S3), which show an epithelial- or 
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mesenchymal-like gene signature, respectively 27. Accordingly, we predict that in women 
with aggressive basal breast cancers in which CerS6 is not expressed, a slight increase in the 
level of C16-ceramide may help to reduce their elevated risk of metastatic dissemination. 
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Materials and Methods 
Cell lines  
The human cell lines derived from hematological cell lineage (Jurkat, CEM, H9, HL60, 
SKW6.4, K562, MOLT4, SR) were cultured in RPMI supplemented with 8% (v/v) heat-
inactivated fetal calf serum (FCS) and 2 mM L-glutamine at 37°C in a 5% CO2 incubator. All 
other cancer cell lines were cultured in DMEM supplemented with 8% (v/v) heat-inactivated 
FCS and 2 mM L-glutamine at 37°C in a 5% CO2 incubator. The NCI-60 collection of human 
tumor cell lines came from Charles River Laboratories (Wilmington, MA, USA). Other cells 
were purchased from American Type Culture Collection (LGC Standards, Molsheim, France). 
The human mammary epithelial cell line MCF10A is spontaneously immortalized but not 
transformed. MCF10A cells infected with LXSN-K-RasV12 or an empty vector were kindly 
provided by Dr. B. H. Park (Baltimore, MD, USA) 16. MCF10A cells were grown in 
DMEM/F12 medium supplemented with 5% horse serum, EGF (20 ng/mL), insulin (10 
µg/mL), cholera toxin (100 ng/mL), and hydrocortisone (0.5 µg/mL) at 37°C in a 5% CO2 
incubator. HMECs infected with a retrovirus carrying hTERT, Ras, and AgT were kindly 
provided by Dr R. A. Weinberg (Cambridge, MA, USA) 4. HMECs immortalized by hTERT 
and Ras were designated HMEC-TR. 
 
In vitro motility assay 
Boyden chambers contained membranes with a pore size of 8 µm (Millipore, Molsheim, 
France). After hydration of the membranes, mesenchymal cells (105 cells per chamber) or 
epithelial cells (3×105 cells per chamber) were added to the top chamber in low serum (1%)-
containing medium. The bottom chamber was filled with low serum (1%)-containing medium 
in the presence or absence of cl-CD95L (100 ng/mL). Cells were cultured for 24 h at 37°C. 
To quantify migration, cells were mechanically removed from the top side of the membrane 
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using a cotton-tipped swab, and migrating cells from the reverse side were fixed with 
methanol and stained with Giemsa. For each experiment, five representative pictures were 
taken for each insert, then cells were lyzed and absorbance at 560 nm correlated to the amount 
of Giemsa stain was measured.  
 
EPR 
Membrane fluidity was determined by a spin-labeling method using EPR, as previously 
described 28. Briefly, plasma membranes of living cells were labeled by incubating cells for 
15 min at 37°C with 12-doxyl stearic acid (36 μg/mL), a fatty acid with a stable nitroxide 
radical ring at the C-12 position. Cells were then washed twice with PBS to remove excess 
12-doxyl stearic acid and EPR spectra of the labeled samples were acquired at ambient 
temperature on a Bruker Elexsys EPR spectrometer operating at 3509.25 G center field, 20 
mW microwave power, 9.86 GHz microwave frequency, 1.77 G modulation amplitude, and 
100 kHz modulation frequency. Fluidity of the spin-labeled membranes was quantified by 
calculating the S parameter. An increase in the S parameter reflects a decrease in membrane 
fluidity, and vice versa. 
 
Immunoblotting 
Cells were lyzed for 30 min at 4°C in lysis buffer (25 mM HEPES pH 7.4, 1% (v/v) Triton X-
100, 150 mM NaCl, and 2 mM EGTA supplemented with a mixture of protease inhibitors). 
Protein concentration was determined by the bicinchoninic acid method (Pierce, Rockford, IL, 
USA) according to the manufacturer's protocol. Proteins were resolved by 8, 10, or 12% SDS-
PAGE and transferred to a nitrocellulose membrane (GE Healthcare, Buckinghamshire, UK). 
The membrane was blocked for 15 min with TBST (50 mM Tris, 160 mM NaCl, and 0.05% 
(v/v) Tween 20, pH 7.4) containing 5% (w/v) dried skimmed milk (TBSTM), and was then 
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incubated overnight at 4°C with the primary antibody diluted in TBSTM. The membrane was 
washed with TBST and was then incubated with peroxidase-labeled anti-mouse IgG1 or 
IgG2a (CliniSciences, Nanterre, France) for 45 min. Proteins were visualized using the 
enhanced chemiluminescence substrate kit (ECL RevelBlOt®, Ozyme, Saint Quentin en 
Yvelines, France). 
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Figure Legends 
 
Figure 1. Plasma membrane fluidity is a pivotal biophysical parameter modulating 
breast cancer cell motility. A. Left panel: Migration of the indicated epithelial and 
mesenchymal-like breast tumor cells was assessed using the Boyden chamber assay in the 
presence or absence of cl-CD95L (100 ng/mL) for 24 h. Migrating cells were stained with 
Giemsa. For each experiment, five images of random fields were acquired. A representative 
image is shown. Bars=70 μm. Right panel: Giemsa-stained cells that migrated to the lower 
side of the membrane were lysed and absorbance was measured at a wavelength of 560 nm. 
B. Upper panel: Membrane fluidity of mesenchymal (Hs578T, MDA-MB-231, MDA-MB-
468, H9, SKW6.4, U251 and Caki-1) and epithelial (MCF-7, T47D, ZR75-1, CEM, Jurkat, 
HCT116 and HL60) cancer cell lines was assessed using EPR. Statistical analyses were 
performed using the non-parametric Mann-Whitney U test (***, p<0.001). Lower panel: 
Membrane fluidity was measured in epithelial (MCF-7, T47D, and ZR75-1) and 
mesenchymal (Hs578T, MDA-MB-231, and MDA-MB-468) breast tumor cells. Statistical 
analyses were performed using the non-parametric Mann-Whitney U test (**, p<0.01). C. The 
mesenchymal cell line MDA-MB-231 was pre-incubated with the membrane stabilizing agent 
UDCA (100 μM) or the fluidizing agent A2C (5 μM) for 30 min and then incubated with or 
without cl-CD95L (100 ng/mL) for 24 h. Membrane fluidity was quantified by EPR. Values 
are means ± SEM of three to five independent experiments (*, p<0.05). D. The Boyden 
chamber assay was used to assess the migration of MDA-MB-231 cells pre-incubated with 
UDCA (100 μM) or A2C (5 μM) for 30 min and then stimulated with or without cl-CD95L 
(100 ng/mL) for 24 h. Giemsa-stained cells that migrated to the lower side of the membrane 
(left panel) were lysed and absorbance at 560 nm was measured (right panel). Values 
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represent the means ± SEM of three independent experiments. * p<0.05 calculated using the 
two-tailed Mann-Whitney U test.  
 
Figure 2. EMT triggers down-regulation of CerS6 expression. A. Comparative levels of 
CerS6 transcripts in Type I (Hs578T, MDA-MB-231, MDA-MB-468, H9, SKW6.4, U251 
and Caki-1) and Type II (MCF-7, T47D, ZR75-1, CEM, Jurkat, HCT116 and HL60) cell lines 
using quantitative PCR. Fold change was calculated as follows: 2-(Ct sample-Ct housekeeping gene)-(Ct 
Mean reference set of cells-Ct housekeeping gene), where the fold change in the mRNA level is relative to that 
in a set of four reference cell lines (Hs578T, H9, CEM, and ZR75-1). Statistical analyses were 
performed using the non-parametric Mann-Whitney U test (***, p<0.001). Values represent 
medians and interquartiles of three independent experiments. B. 47 cancer cells of the NCI-60 
cell line collection were ranked according to their ratio of E-cadherin/Vimentin expression. 
Undefined cell lines express either both or no markers. The E-cadherin/Vimentin ratio was 
assessed by densitometry analysis of the data shown in Fig.S2A. C. Protein levels of CerS6 
were quantified by densitometry analysis of data shown in Fig.S2A and compared between 
epithelial and mesenchymal-like tumor cells. Statistical analyses were performed using the 
non-parametric Mann-Whitney U test (**, p<0.01). Values represent medians and 
interquartiles. N depicts number of cells present in each lineage. D. Schematic representation 
of the successive steps of the transformation of primary HMECs infected with hTERT, small-t 
and large-T antigens of SV40, and H-RasV12. Cells were lyzed and 100 μg of protein was 
loaded per lane. Western blotting was performed with the indicated antibodies.  
 
Figure 3. CerS6 overexpression in mesenchymal tumor cells increases the level of C16:0 
ceramide, decreases plasma membrane fluidity, and inhibits cell migration. A. MDA-
MB-231 or MDA-MB-468 breast cancer cells were transduced with a retroviral vector 
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encoding HA-tagged wild-type CerS6 (CerS6-HA) or a control vector (Mock). Indicated cells 
were lyzed and immunoblotting was performed. B. Ceramide levels were determined by mass 
spectrometry. Values are means ± SEM of three independent experiments. *, p<0.05. C. 
Indicated cells were incubated in the presence or absence of cl-CD95L (100 ng/mL) for 30 
min. Membrane fluidity was assessed by EPR. Values are means ± SEM of four independent 
experiments. *, p<0.05. D. The Boyden chamber assay was used to assess the migration of 
MDA-MB-468 (left panels) and MDA-MB-231 (right panels) cells cultured with or without 
cl-CD95L (100 ng/mL) for 24 h. Migrating cells were stained with Giemsa. For each 
experiment, five images of random fields were acquired. A representative image is shown. 
Bars=70 μm. Giemsa-stained migrating cells were lysed and absorbance at 560 nm was 
recorded. Values are means ± SEM of three independent experiments (* p<0.05; ns, not 
significant).  
 
Figure 4. Silencing of CerS6 in epithelial breast cancer cells reduces the level of C16:0 
ceramide, increases plasma membrane fluidity, and promotes cell migration. A. MCF7 
and T47D breast cancer cells were transduced with lentiviruses encoding scrambled or CerS6-
targeting shRNA (shCerS6 #236 and #241). Infection efficiency was monitored by examining 
the level of GFP expression using flow cytometry. B. Down-regulation of CerS6 was 
confirmed by immunoblotting. β-actin was used as a loading control. C. Ceramide species 
were quantified by mass spectrometry in the indicated cell populations. Values are means ± 
SD of three independent experiments (*p<0.05, **p<0.01, ***p<0.001). D. Membrane 
fluidity was assessed by EPR using a spin-labeling method. E. Cell migration was assessed 
using Boyden chambers. Migrating cells were stained with Giemsa and lysed, and then 
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absorbance at 560 nm was recorded. Values represent means ± SEM of three independent 
experiments (*p<0.05). 
 
Figure 5. Treatment of mesenchymal breast cancer cells with exogenous C16:0 ceramide 
reduces plasma membrane fluidity and prevents basal and CD95-mediated cell 
migration. A. MDA-MB-468 and MDA-MB-231 cells were treated for 24 h with the 
indicated concentration of C16:0 ceramide. Cell death was quantified using the MTT assay 
(metabolic activity). B. The indicated cells were pre-incubated with or without a non-
cytotoxic dose (1 μM) of C16:0 ceramide (C16-Cer) for 60 min, and were then incubated with 
or without cl-CD95L (100 ng/mL) for 30 min. Membrane fluidity was assessed by EPR. 
Values are means ± SEM of four independent experiments (*, p<0.05; ns, not significant). C. 
Indicated cells were pretreated with or without C16:0 ceramide (1 μM) for 60 min and were 
then incubated with or without cl-CD95L (100 ng/mL) for 24 h. Cell migration was assessed 
by the Boyden chamber assay. Bars=70 μm. Giemsa-stained cells that migrated to the lower 
side of the membrane were lysed and absorbance at 560 nm was recorded. Values represent 
the means and SEM of three independent experiments (* p<0.05). 
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Table 1. Lipidomic analysis of MDA-MB-231 cells infected with mock or CerS6-HA-
encoding retroviruses. Data are means ± S.E.M. of three independent experiments (**, 
p<0.01). 
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Table 2. Lipidomic analysis of MDA-MB-468 cells infected with mock or CerS6-HA-
encoding retroviruses. Data are means ± S.E.M. of three independent experiments (**, 
p<0.01). 
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Table 3. Lipidomic analysis of MCF7 cells infected with lentiviruses encoding scrambled 
or CerS6-targeting shRNA. Data are means ± S.E.M. of three independent experiments (*, 
p<0.05, **, p<0.01). 
 
 
  
 Lipids  
(nmol/mg of proteins) 
MCF7  
Scrambled 
MCF7  
shCerS6#236 
MCF7 
shCerS6#241 
    
Ceramide 0.232 ± 0.049 0.237 ± 0.027 0.257 ± 0.023 
Sphingomyelin 3.07 ± 0.456 5.07 ± 0.303 * 4.27 ± 0.2 p=0.05 
C16:0-Sphingomyelin 1.04 ± 0.09 0.63 ± 0.039 * 0.56 ± 0.049 ** 
Phosphatidylcholine 41.69 ± 4.294 48.76 ± 1.622 51.70 ± 6.01 
Phosphatidylethanolamine 18.54 ± 0.813 22.57 ± 1.64 p=0.06 22.26 ± 0.85 * 
Phosphatidylserine 0.917 ± 0.106 1.091 ± 0.115 1.013 ± 0.064 
Phosphatidylinositol 3.38 ± 0.606 4.76 ± 0.641 4.48 ± 0.6 
Cholesterol 23.77 ± 3.053 23.16 ± 2.187 24.81 ± 0.671 
Diacylglycerol 4.15 ± 2.412 5.75 ± 3.06 6.09 ± 3.719 
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Table 4. Lipidomic analysis of T47D cells infected with lentiviruses encoding scrambled 
or CerS6-targeting shRNA. Data are means ± S.E.M. of three independent experiments (*, 
p<0.05). 
 
 
 
 
Lipids  
(nmol/mg of proteins) 
T47D  
Scrambled 
T47D 
CerS6#236 
T47D  
CerS6#241 
    
Ceramide 0.646 ± 0.078 0.416 ± 0.208 0.626 ± 0.053 
Sphingomyelin 3.52 ± 0.739 3.98 ± 1.396 4.03 ± 0.969 
C16:0-Sphingomyelin 2.16 ± 0.127 1.62 ± 0.54 p=0.09 2.01 ± 0.055 
Phosphatidylcholine 63.74 ± 7.666 47.12 ± 24.968 54.94 ± 8.386 
Phosphatidylethanolamine 23.26 ± 3.354 17.03 ± 8.552 21.83 ± 3.341 
Phosphatidylserine 1.117 ± 0.007 0.768 ± 0.388 1.237 ± 0.098 
Phosphatidylinositol 2.24 ± 0.284 1.09 ± 0.58 p=0.09 1.33 ± 0.163 * 
Cholesterol 29.47 ± 2.473 29.51 ± 2.254 27.52 ± 0.907 
Diacylglycerol 6.68 ± 1.442 11.08 ± 3.979 8.9 ± 2.535 
 





